In The Lancet Infectious Diseases, Marcus Chen and colleagues1 report on the efficacy of solithromycin, a novel fourth generation macrolide, as a treatment option for urogenital gonorrhoea. In the SOLITAIRE-U trial, solithromycin was compared with a combination of ceftriaxone plus azithromycin, which is the standard therapy in many countries. To date, Neisseria gonorrhoeae, the pathogen that causes gonorrhoea, has acquired antimicrobial resistance against all available first-line antibiotic treatment options, including penicillin, tetracycline, ciprofloxacin, and spectinomycin, leading to treatment failure.
Original Article: [Comment] Solithromycin for the treatment of drug-resistant gonorrhoea